Direct and Indirect Costs Associated with Coronary Artery (Heart) Disease in Tabriz, Iran.
coronary heart disease (CHD)
cost-disease analysis
direct cost
indirect cost
Journal
Risk management and healthcare policy
ISSN: 1179-1594
Titre abrégé: Risk Manag Healthc Policy
Pays: England
ID NLM: 101566264
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
05
2020
accepted:
14
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Cardiovascular diseases (CVDs) are the major causes of mortalities worldwide. This study was conducted to evaluate the direct and indirect costs of coronary artery disease (CAD) in Iran. This is a prevalence-based cost-of-illness (COI) study that estimates the direct and indirect costs of CAD. The study conducted over a six-month period from April to September in 2017. Patients were recruited from Madani hospital in Tabriz, Iran. A total of 379 patients were investigated from societal perspective. Direct costs were estimated using the bottom-up costing approach and indirect costs were estimated using the Human Capital (HC) approach. A generalized linear model of regression was used to explore the relation between total cost and socio-demographic variables. The total annual mean cost was compared to Gross Domestic Product (GDP) per capita which was reported in the form of Purchasing Power Parity (PPP) index. To deal with uncertainty, one-way sensitivity analysis was performed. Total costs per patient in one year were estimated to be IRR 63452290.17 ($PPP 7736.19) at a 95% confidence interval (58191511.73-68713068.60), the biggest part of which is related to direct medical costs with IRR 33884019.53 per year ($PPP 4131.18) (54%). Direct non-medical costs were estimated IRR 1655936.68 ($PPP 201.89) per patient (2%) and indirect costs were estimated IRR 27912333.97 per patient ($PPP 3403.11) (44%), which 62% of indirect costs is related to patients' work absenteeism. This study estimates the direct (56%) and indirect (44%) costs associated with CAD. The study explores the essential drivers of the costs and provides the magnitude of the burden in terms of the share of GDP. The outcomes can be used in priority setting, in particular for cost benefit analysis, and adopting new policies regarding insurance coverage and equity issues.
Identifiants
pubmed: 32801971
doi: 10.2147/RMHP.S261612
pii: 261612
pmc: PMC7406327
doi:
Types de publication
Journal Article
Langues
eng
Pagination
969-978Informations de copyright
© 2020 Darba et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur J Health Econ. 2012 Jun;13(3):347-53
pubmed: 21442437
Int J Environ Res Public Health. 2019 Aug 01;16(15):
pubmed: 31374880
Lancet. 2006 Nov 18;368(9549):1828-41
pubmed: 17113432
Health Policy Plan. 2015 Sep;30(7):875-84
pubmed: 25113027
Circulation. 2006 Feb 14;113(6):e85-151
pubmed: 16407573
Cardiovasc Drugs Ther. 2007 Oct;21(5):389-98
pubmed: 17805954
Child Adolesc Psychiatry Ment Health. 2012 Nov 16;6(1):35
pubmed: 23158382
Vojnosanit Pregl. 2016 Jun;73(6):531-7
pubmed: 27498444
Arch Iran Med. 2019 Apr 01;22(4):204-210
pubmed: 31126179
BMJ. 2000 May 13;320(7245):1335
pubmed: 10807635
Risk Manag Healthc Policy. 2020 Feb 25;13:155-162
pubmed: 32161509
Stat Methods Med Res. 1999 Mar;8(1):37-50
pubmed: 10347859
J Natl Cancer Inst. 1995 Mar 15;87(6):417-26
pubmed: 7861461
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Healthcare (Basel). 2019 Aug 21;7(3):
pubmed: 31438602
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
J Prev Med Public Health. 2012 Sep;45(5):291-300
pubmed: 23091654
Open Cardiovasc Med J. 2012;6:141-6
pubmed: 23230452
Clin Mol Hepatol. 2014 Dec;20(4):327-37
pubmed: 25548737
J Gastrointest Cancer. 2020 Mar;51(1):196-203
pubmed: 30977049
J Diabetes Metab Disord. 2017 Jan 23;16:3
pubmed: 28127543
BMC Cardiovasc Disord. 2013 Aug 08;13:55
pubmed: 23924508
Prim Health Care Res Dev. 2018 May;19(3):264-276
pubmed: 29310744
Expert Rev Pharmacoecon Outcomes Res. 2008 Aug;8(4):349-56
pubmed: 20528342
Value Health Reg Issues. 2018 May;15:12-26
pubmed: 29474174
Ann Transl Med. 2016 Jul;4(13):256
pubmed: 27500157
Chronic Dis Can. 2002 Spring;23(2):47-57
pubmed: 12095455